What is the market's earnings forecast for SeaStar Medical next quarter?

What factors drove the changes in SeaStar Medical's revenue and profit?

What were the key takeaways from SeaStar Medical’s earnings call?

What is SeaStar Medical's gross profit margin?

What is SeaStar Medical's latest dividend and current dividend yield?

Did SeaStar Medical beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for SeaStar Medical year over year?

What were the key takeaways from SeaStar Medical's earnings call?

- **Revenue Surge**: 2025 net revenue up 723% to $1.1 million, with 90%+ gross margin.
- **Clinical Momentum**: NEUTRALIZE-AKI trial 54% enrolled (181/339), targeting 2027 readout; pediatric AKI survival rate 76% vs. historical 30-40%.
- **Financial Strength**: $24M capital raise in 2025, $12M cash, 26% expense reduction to $13.4M, net loss narrows to $1.2M.
- **Pipeline Expansion**: SCD therapy for CRS-CRS trial underway; potential 2027 PMA submission for adult AKI under Breakthrough Designation.

**【CEO Opening Remarks】**
- **Revenue Growth**: Net revenue from QUELIMMUNE reached $1.1 million in 2025, up from $135,000 in 2024, with a 90%+ gross margin.
- **Customer Expansion**: Added 13 new customers in 2025, bringing total to 16, targeting 15 more in 2026 for $2 million in pediatric sales.
- **Clinical Milestones**: NEUTRALIZE-AKI trial (adult AKI) at 54% enrollment (181/339), aiming for completion by end-2026. SCD therapy for CRS-CRS (cardiorenal syndrome) trial initiated with NIH funding.
- **Financial Health**: Raised $24 million in 2025, reducing operating liabilities by $3 million, with $12 million cash as of Q4 2025.

**【Commercial & Clinical Updates】**
- **QUELIMMUNE Momentum**: Q4 2025 sales $315,000, Q1 2026 already exceeded this. 15 new sites targeted in 2026, with 6 added in Q1.
- **Clinical Data**: SAVE registry (FDA-mandated) completed enrollment of 50 patients, showing 76% 90-day survival vs. historical 30-40%.
- **Trial Progress**: NEUTRALIZE-AKI on track for 2027 readout; SCD therapy for CRS-CRS using intermittent dosing to expand potential outpatient use.

**【Financial Performance】**
- **Revenue Growth**: 2025 net revenue $1.1 million (vs. $135,000 in 2024), with Q4 2025 gross margin >90%.
- **Expense Management**: Operating expenses reduced 26% YoY to $13.4 million in 2025, net loss narrowed to $1.2 million (vs. $24.8 million in 2024).
- **Balance Sheet**: $12 million cash as of Q4 2025, up from $1.8 million in 2024, with no debt.

**【Q&A Highlights】**
- **Manufacturing Confidence**: Contract manufacturer Fresenius Medical (dialysis leader) ensures sufficient SCD supply for both pediatric and adult markets.
- **Regulatory Pathway**: Potential modular PMA for adult AKI under Breakthrough Device Designation; pediatric AKI approved via Humanitarian Use Exemption.
- **Financial Outlook**: 2026 spending expected to align with 2025 run rate, driven by clinical trial expansion and commercial infrastructure.
- **Pipeline Expansion**: SCD therapy for CRS-CRS could qualify for humanitarian designation, enabling faster access for ultra-rare patient populations.

SeaStar Medical Holding Corp (ICU) Q4 2025 Earnings Call Transcript

- **Revenue Milestone**: Q3 revenue of $183,000, on track for over $1 million in 2025, with Q4 sales surpassing Q3 levels.
- **Clinical Expansion**: NEUTRALIZE-AKI trial enrolling 146/339 patients across 17 sites, targeting 25 sites by year-end.
- **Financial Strength**: $13.8 million cash, raised $12.4 million, supporting clinical trial expansion.
- **Strategic Growth**: Quellimune adoption in 10 commercial sites, aiming for a $100 million market with 76% patient survival rates.

**Management Opening Remarks**
- Jackie Cossman provided an overview of the call, emphasizing forward-looking statements and risks associated with SeaStar Medical's operations.

**CEO Summary Section**
- **Revenue Growth**: Reported Q3 net revenue of $183,000, up from $68,000 in Q3 2024, with Q4 sales already exceeding Q3 levels. Full-year 2025 revenue expected to exceed $1 million.
- **Gross Margin**: Achieved a 92% gross profit margin in Q3, marking the first quarter of commercial sales.
- **Clinical Trials**: Expanded the NEUTRALIZE-AKI trial to 17 sites, enrolling 146 patients toward a target of 339. Launched a new CRS trial for cardiorenal syndrome, targeting 20 patients.
- **Strategic Focus**: Highlighted the potential of Quellimune therapy in treating hyperinflammation and its broader market application beyond AKI.

**Commercial Update**
- **Site Activation**: 10 active commercial sites, with four new additions in Q3. Q4 sales already surpassing Q3 levels.
- **Market Expansion**: Aiming to capture a $100 million U.S. market, focusing on simplifying adoption processes and cross-functional collaboration with hospitals.
- **Operational Efficiency**: Streamlined site activation processes, reducing adoption timelines from six months to a more accelerated pace.

**CMO Clinical Update**
- **NEUTRALIZE-AKI Trial**: 146 patients enrolled (target 339) across 17 sites, with safety data approved by the DSMB. Expanded to 25 sites to meet enrollment by end-2026.
- **Quellimune Registry**: 76% survival rate in 21 pediatric patients, supporting real-world evidence for FDA interactions.
- **CRS Trial**: Launched a single-arm study for cardiorenal syndrome, targeting 20 patients to demonstrate SCD therapy feasibility in chronic settings.

**CFO Financial Commentary**
- **Revenue**: Q3 net revenue $183,000 (92% gross margin), up 170% year-over-year.
- **Cost Management**: Operating expenses down 18% to $3.7 million, driven by reduced consulting and R&D costs.
- **Financial Health**: Cash balance of $13.8 million, raised $12.4 million in Q3, extending runway.
- **Net Loss**: $3.5 million for Q3, reflecting ongoing clinical trial investments.

**Q&A Highlights**
- **Trial Enrollment**: Projected to meet 339-patient target by end-2026 with 25 activated sites. Adjustments will be made if enrollment slows.
- **CRS Trial Progress**: Expected to enroll 20 patients within a year, leveraging existing NEUTRALIZE-AKI sites.
- **Revenue Visibility**: Q4 sales already exceed Q3, with a focus on reducing revenue variability through site expansion.

SeaStar Medical Holding Corp (ICU) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 revenue up 15% ($338K), YTD $631K, with 370% YTD growth in Quellimmune adoption.
- **Trial Progress**: Neutralized AKI trial enrolling 125/200 patients; interim analysis completed, DSMB recommendation expected Q3.
- **Market Potential**: Adult AKI market of 200K patients annually, $4B potential, with FDA breakthrough designation for 5 indications.
- **Financial Health**: Gross margin 92%, operating expenses down 55%, net loss reduced to $2M, $6.3M cash post-Q2 raise.
- **Strategic Focus**: Completing pivotal trial, filing PMA for adult AKI, and expanding Quellimmune adoption.

**【CEO Opening Remarks】**
- Enrolled 125 patients in the neutralized AKI trial, with 3 new Quellimmune customers from top US children's hospitals.
- Q2 net revenue increased 15%, YTD growth of 370%, driven by pediatric adoption.
- Positive survival results from 20 pediatric patients in the SAVE registry (75% 28-day survival).
- Raised $12.4M post-Q2 to strengthen balance sheet.
- Anticipate lumpy sales but expect sequential growth in Quellimmune adoption.

**【Commercial Achievements】**
- Q2 revenue up 15%, YTD $631K, with 3 new customers (e.g., Texas Children's Hospital).
- Planning to present expanded SAVE registry data at a pediatric nephrology meeting.
- Adult SCD therapy market: 200K annual patients, $4B potential, with FDA breakthrough designation for 5 additional indications.
- Pre-commercialization efforts leveraging pediatric experience for faster adult adoption.

**【CMO Update】**
- Neutralized AKI trial: 125/200 patients enrolled (31 new in Q2), interim analysis of 100 patients completed.
- DSMB recommendation expected in Q3; 80% of eligible patients consented.
- Enrichment criteria: CRP >3.5 mg/dL to target inflammatory patients.
- Aiming to add 3-4 sites by Q3 end; 75% survival in 20 pediatric registry patients.

**【CFO Financial Commentary】**
- Q2 revenue $338K, 15% QoQ growth, gross margin 92%.
- Operating expenses down 55% to $2.1M, net loss $2M (down 37%).
- Cash $6.3M; raised $12.4M post-Q2 for trial completion and PMA filing.
- Focus on adult AKI market, with potential PMA filing in 2026 if trial successful.

**【CEO Closing Remarks】**
- Excited about adult AKI market potential ($4B) and FDA breakthrough designation.
- Plan to file PMA in 2026 if trial meets primary endpoint.
- Emphasizes value creation for investors through life-saving therapies and market expansion.

SeaStar Medical Holding Corp (ICU) Q2 2025 Earnings Call Transcript

- **Revenue Surge**: Q1 2025 revenue jumped 4x to $293K, fueled by new pediatric hospital activations and repeat orders.
- **Adult AKI Trial Milestone**: NEUTRALIZE-AKI trial reached 50% enrollment (100 patients), with interim DSMB analysis due in Q3.
- **$4.5B Market Opportunity**: Adult AKI requiring CRRT affects 200K+ U.S. patients annually, with no FDA-approved treatments.
- **Pipeline Expansion**: Two new FDA breakthrough designations target cardiac surgery patients, aligning with hospital resource needs.
- **Cost Efficiency**: Operating expenses down 5% YOY to $4.1M, supporting lean execution of clinical and commercial goals.

**【CEO Summary Section】**
- Q1 2025 revenue increased fourfold to $293,000, driven by repeat orders from existing pediatric AKI customers and new hospital activations.
- Achieved 50% enrollment (100 patients) in the NEUTRALIZE-AKI trial for adult AKI, with an interim DSMB analysis expected in Q3 2025.
- Expanded pipeline with two new FDA breakthrough device designations for adult and pediatric cardiac surgery, targeting over 200,000 annual adult AKI patients ($4.5B market opportunity).

**【CFO Financial Commentary】**
- Q1 2025 net loss narrowed to $3.7M (vs. $12.7M in Q1 2024), with operating expenses down 5% year-over-year to $4.1M due to cost control.
- Cash balance of $5.3M as of Q1 2025, supporting ongoing clinical trials and commercial expansion.
- 2025 priorities: pediatric site activations, NEUTRALIZE-AKI enrollment completion, and PMA filing preparation.

**【Q&A Key Highlights】**
- 15 active sites in the adult AKI trial, with 5 more planned by Q3 2025.
- 6 commercial pediatric sites, with multiple others in IRB approval process.
- Breakthrough designations for cardiorenal and hepatorenal syndromes could enable rapid post-AKI market expansion.
- Word-of-mouth adoption among pediatric hospitals is accelerating site activations despite lengthy IRB processes.

Actual	-10	-6.25	-9.25	-4.75	-4.75	-1.03	-1.1	-0.9	-0.44	-0.18	-0.13	-0.8
Forecast	-5	-6.25	-6.25	-3.25	-3.75	-1.41	-1.13	-0.89	-0.52	-0.43	-0.15	-1.08
Surprise	-100.00%	0.00%	-48.00%	-46.15%	-26.67%	+26.95%	+2.65%	-1.12%	+15.38%	+58.14%	+13.33%	+25.93%

Actual	--	--	--	--	0	0	68.00K	67.00K	293.00K	338.00K	183.00K	420.00K
Forecast	--	--	50.00K	175.00K	150.00K	0	75.00K	150.00K	150.00K	200.00K	250.00K	222.50K
Surprise	0.00%	0.00%	0.00%	0.00%	-100.00%	0.00%	-9.33%	-55.33%	+95.33%	+69.00%	-26.80%	+88.76%

ICU

ICU fundamentals

ICU Q4 2025 Earnings

Earnings Call

You can ask Aime

ICU

ICU fundamentals

ICU Q4 2025 Earnings

Earnings Call

ICU Earnings Call Summary for Q4/20254:30 PM on Mar 25, 2026

ICU Earnings Call Summary for Q3/20254:30 PM on Nov 13, 2025

ICU Earnings Call Summary for Q2/20254:30 PM on Aug 13, 2025

ICU Earnings Call Summary for Q1/20254:30 PM on May 14, 2025

ICU Earnings Call Summary for Q4/20244:30 PM on Mar 27, 2025

You can ask Aime